Effect of Anti-Iduronate 2-Sulfatase Antibodies in Patients with Mucopolysaccharidosis Type II Treated with Enzyme Replacement Therapy - 15/09/22
Abstract |
Objective |
To assess the relationship between anti-Iduronate 2-sulfatase (IDS) antibodies, IDS genotypes, phenotypes and their impact in patients with enzyme replacement therapy (ERT)-treated Mucopolysaccharidosis type II.
Study design |
Dutch patients treated with ERT were analyzed in this observational cohort study. Antibody titers were determined by enzyme-linked immunosorbent assay. Neutralizing effects were measured in fibroblasts. Pharmacokinetic analysis of ERT was combined with immunoprecipitation. Urinary glycosaminoglycans were measured using mass spectrometry and dimethylmethylene blue.
Results |
Eight of 17 patients (47%) developed anti-IDS antibodies. Three patients with the severe, neuronopathic phenotype, two of whom did not express IDS protein, showed sustained antibodies for up to 10 years of ERT. Titers of 1:5120 or greater inhibited cellular IDS uptake and/or intracellular activity in vitro. In 1 patient who was neuronopathic with a titer of 1:20 480, pharmacokinetic analysis showed that all plasma recombinant IDS was antibody bound. This finding was not the case in 2 patients who were not neuronopathic with a titer of 1:1280 or less. Patients with sustained antibody titers showed increased urinary glycosaminoglycan levels compared with patients with nonsustained or no-low titers.
Conclusions |
Patients with the neuronopathic form and lack of IDS protein expression were most at risk to develop sustained anti-IDS antibody titers, which inhibited IDS uptake and/or activity in vitro, and the efficacy of ERT in patients by lowering urinary glycosaminoglycan levels.
Le texte complet de cet article est disponible en PDF.Keywords : mucopolysaccharidosis, mucopolysaccharidosis type II, MPS II
Abbreviations : CRIM, DMB, DS, ERT, GAG, HS, IAR, IDS, MPS II, PBS, uGAG, uDS, uHS
Plan
| A.v.d.P. had no conflict of interests concerning any aspect of the current study. However, she gives advice to several pharmaceutical companies about the implementation and development of innovative therapies, mainly for Pompe disease, but also for other LSDs and neuromuscular disorders. Furthermore, she received funds for research via agreements between Erasmus MC and pharmaceutical companies. She also advices public or private charities, who aim to improve the care for patients with metabolic diseases. The other authors declare no conflicts of interest. |
Vol 248
P. 100 - septembre 2022 Retour au numéro
Article précédent
- Predictors of Patient Return to a Tertiary Neurofibromatosis Subspecialty Clinic
- Kyra L. Rosen, Olivia Cobb, Deann Gavney, Stephanie M. Morris, David H. Gutmann
- The Genomics of Congenital Diaphragmatic Hernia: A 10-Year Retrospective Review
- K. Taylor Wild, Erica Schindewolf, Holly L. Hedrick, Natalie E. Rintoul, Tiffiney Hartman, Juliana Gebb, Julie S. Moldenhauer, Elaine H. Zackai, Ian D. Krantz
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?